GENB NASDAQ
Generate Biomedicines, Inc.
1W: -9.6%
1M: -15.9%
3M: -19.1%
YTD: +8.2%
$13.69
-0.11 (-0.80%)
Weekly Expected Move ±8.3%
$11
$13
$14
$15
$16
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Squarepoint Ops LLC Makes New $530,000 Investment in Generate Biomedicines Inc $GENB
AI Could Eventually Crack Cancer and Drug Discovery, Says Arm CEO — But This Is What’s Holding It Back
Generate Biomedicines Inc. to Participate in September Investor Conferences
Five September talks will stream online from Generate Biomedicines - Stock Titan
How Nvidia’s Investment Juggernaut Can Jump from Big to Enormous
Frances Arnold plans 2026 stock sale in Generate Biomedicines (NASDAQ: GENB) - Stock Titan
Director at Generate Biomedicines (GENB) lines up a major stock sale - Stock Titan
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30 - moomoo.com
EXCLUSIVE: Nvidia GPUs Are Essential—But They Won't Decide Who Wins AI Drug Discovery, Generate CTO Says
Cathie Wood Sends a $20 Million Signal on Broadcom Stock
Companies Like Generate Biomedicines (NASDAQ:GENB) Are In A Position To Invest In Growth - simplywall.st
Market Movers | Winners: ANF, GTN-A, CAPR | Losers: GENB, EMAT, SYRE - Trefis
We're Hopeful That Generate Biomedicines (NASDAQ:GENB) Will Use Its Cash Wisely - moomoo.com
Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On Returns - Yahoo Finance
Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On Returns
Generate Biomedicines Stock Slides 20% as 103 Million Shares Clear Lock-Up - TechStock²
Biotech Stocks At 52-Week Highs - GENB +15%, BDSX +10%, CDNA +6%, CPIX +10%, CRDL +7% - RTTNews
$Generate Biomedicines (GENB.US)$ - Moomoo
Certain Stock Options of Generate Biomedicines, Inc. are subject to a Lock-Up Agreement Ending on 26-AUG-2026. - marketscreener.com
Generate Biomedicines surges again, rises 12% to new high (GENB:NASDAQ) - Seeking Alpha
Generate Biomedicines Shares Up 12% as 103 Million-Share Placement Looms - TechStock²
$Generate Biomedicines (GENB.US)$ shoutout to god - Moomoo
Generate Biomedicines stock jumps as post-IPO lock-up set to expire
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Market Movers | Winners: CYPH, FWDI, GENB | Losers: RGNX, AIAI, TMS - Trefis
Generate (GENB) Move: Ends Higher by 0.81% at $16.12 in the Latest Session; Market Levels: the Near-Term Reference Band Stretches From $15.31 to $16.93 in Latest Trading - MA Cross Alert - dars.gov.et
Generate (GENB) Move: Ends Higher by 0.81% at $16.12 in the Latest Session; Market Levels: the Near-Term Reference Band Stretches From $15.31 to $16.93 in Latest Trading - Sign of Strength - vinanet.vn
8 Stocks Nvidia Has Invested In - US News Money
Nvidia Holds More Than 122 Million Shares of SPCX Stock After Q2. Barchart Data Shows It’s Making a High-Upside Bet.
Two Positions Make Up 80% of Nvidia's $63.4 Billion Portfolio
Nvidia discloses big stake in SpaceX in Q2 moves
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines (GENB) posts Q2 loss but holds $457.4M cash after IPO - Stock Titan
Generate Biomedicines, Inc. - Common Stock (Nasdaq:GENB) Stock Quote - The Chronicle-Journal
This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It
This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It
This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It - The Motley Fool
Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?
Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday
Tesla, AMD, and SpaceX headline Cathie Wood's biggest H1 portfolio bets
If You Invested $1,000 in Generate Biomedicines (GENB) - Stock Titan
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB) - Yahoo Finance
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts
$GENB stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains - Yahoo Finance
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains
Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x - simplywall.st
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer - The Globe and Mail
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
GENB News | GENERATE BIOMEDICINES INC (NASDAQ:GENB) - ChartMill
Generate Biomedicines (GENB) Stock News - Stock Titan
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
$GENB stock is down 8% today. Here's what we see in our data. - Quiver Quantitative
Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer? - simplywall.st
A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment - simplywall.st
This AI Biotech Stock Landed a $10.4 Million Nvidia Investment - Barchart.com
A Deep Dive Into NVIDIA’s Latest Portfolio Moves
A Deep Dive Into NVIDIA’s Latest Portfolio Moves
$GENB stock is down 17% today. Here's what we see in our data. - Quiver Quantitative
Trades Update - Buying More Generate Biomedicines - DeepDive - Moomoo
Flagship entities disclose large GENB holdings, Flagship Pioneering holds 48.9% (GENB) - Stock Titan
Generate Biomedicines (NASDAQ: GENB) exec Michael Nally holds 5.2% stake - Stock Titan
Generate Biomedicines (GENB) 10K Form and Latest SEC Filings 2026 - MarketBeat
GENB: Generate Biomedicines, Inc. - Brokerage Recommendations Chart - Zacks Investment Research
Generate Biomedicines, Inc. Stock 12‑Month Price Target Raised to $25.4, Implies 57% Upside - TradingView
Generate Biomedicines, Inc. (GENB) Ps Ratio (TTM) - Zacks Investment Research
GENB: Generate Biomedicines, Inc. - Comparative Chart - Zacks Investment Research
Dividend History - Generate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) - Zacks Investment Research
Should I buy Generate Biomedicines, Inc. (GENB) - Zacks Investment Research
New Analyst Forecast: $GENB Given $25 Price Target - Quiver Quantitative
Generate Biomedicines, Inc. reports Q1 results
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
After a $369.3M IPO, Generate targets 2 first-patient cancer trials in 2026 - Stock Titan
$GENB stock is up 10% today. Here's what we see in our data. - Quiver Quantitative
Generate Biomedicines, Inc. - GENB - Stock Price Today - Zacks Investment Research
H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating
H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating - Yahoo Finance
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Largest IPOs of the last 90 days register mixed debut
Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler
Catalyst Watch: Eyes on post-Iran economic data, Fedspeak, and cybersecurity
Generate Biomedicines (GENB) Valuation Check After Recent Share Price Weakness
Generate Biomedicines (GENB) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Assessing Generate Biomedicines (GENB) Valuation After Recent Share Price Volatility - simplywall.st
Cathie Wood's weekly recap: adds defense stock Kratos, CoreWeave, Baidu
GENB: Generate Biomedicines Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits